Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Guberina, Maja; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Heinzelmann, Frank; Cheufou, Danjouma; Kimmich, Martin; Friedel, Godehard; Schmidberger, Heinz; Darwiche, Kaid; Jendrossek, Verena; Schüler, Martin; Stamatis, Georgios; Pöttgen, Christoph

doi:10.1093/annonc/mdx069

Cited by 41 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is unclear which regions of the heart are most susceptible for radiation injury. The contribution of heart doses to mortality has not been consistently demonstrated [129][130][131], but it is preferred that heart doses be limited as much as possible.…”

Section: Fractionation For Stereotactic Body Radiotherapy (Sbrt)mentioning

confidence: 99%

European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer

Ruysscher

Faivre-Finn

Moeller

et al. 2017

Radiotherapy and Oncology

182

119

View full text Add to dashboard Cite

show abstract

Section: Fractionation For Stereotactic Body Radiotherapy (Sbrt)mentioning

confidence: 99%

European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer

Ruysscher

Faivre-Finn

Moeller

et al. 2017

Radiotherapy and Oncology

182

119

View full text Add to dashboard Cite

show abstract

“…Prior studies in this setting focused primarily on the association between cardiac dosimetry and OS, reaching conflicting conclusions. [10][11][12][13] Furthermore, the data appear limited about the significance of specific types of cardiotoxicities and the relationship with doses to cardiac subvolumes. 14 We thus assessed these relationships within a modern cohort of inoperable NSCLC patients treated with curative standard-dose RT (median prescribed dose, 61.2 Gy) and concurrent chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC

Yegya-Raman

Wang

Kim

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…5 A large number of studies have shown that RIHD can occur in patients with breast cancer, childhood lymphoma, and other cancers decades after radiotherapy. [6][7][8] Until now, there was no standard diagnostic method for RIHD. Myocardial markers (including brain natriuretic peptide (BNP), pro-BNP, and cTnI), echocardiography, and cardiac magnetic resonance are common methods for diagnosing RIHD.…”

Section: Introductionmentioning

confidence: 99%

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Zeng

Zhou

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Abbreviations: BNP, B-type natriuretic peptide; DVH, dose-volume histogram; IMRT, intensity-modulated radiotherapy; IQR, interquartile range; LVEF, the left ventricle ejection fraction; MHD, mean heart dose; M-LAD, mean dose of left anterior descending artery; RIHD, radiation-induced heart disease; RT, radiotherapy; sST-2, solubleST-2; VMRT, volumetric-modulated radiotherapy. AbstractBackground: Early screening and diagnosis of radiation-induced heart disease (RIHD)is difficult in patients with chest radiation exposure. sST-2 is involved in myocardial stress or injury. We evaluated the relationship between heart dose parameters and sST-2 changes in chest malignant tumor patients who received chest radiation. Methods:We prospectively collected thoracic malignancy cancer patients who had received chest radiotherapy. Heart dosimetry parameters were extracted from the treatment planning system. sST-2 was measured at baseline, the middle stage, and after radiotherapy (recorded as pre-ST-2, mid-ST-2, and post-ST-2). sST-2 change rate was calculated. Scatter plots showed the relationship between cardiac dose parameters and ST-2 change rate. Multiple regression was used to analyze the relationship between cardiac dose parameters and ST-2 change rate. Results:Totally, 60 patients were enrolled. The mean V 5 , V 10 , V 20 , V 30 , V 40 , and MHD was 60.93 ± 27.79%, 51.43 ± 25.44%, 39.17 ± 21.75%, 28.07 ± 17.15%,18.66 ± 12.18%, and 18.60 ± 8.63 Gy, respectively. The median M-LAD was 11.31 (IQR 3.33-18.76) Gy. The mean pre-ST-2, mid-ST-2, and post-ST-2 was 5.1 ± 3.8, 6.4 ± 3.9, and 7.6 ± 4.4, respectively. sST-2 was elevated with thoracic irradiation (P < .001). Multivariate linear regression analyses showed that V 5 , V 10 , V 20 , and MHD were independently and positively associated with ST-2 change rate (β = .04, .04, .04, and .10, respectively, all P < .05). Conclusion: Serum sST-2 levels were elevated over time during radiotherapy. V 5 , V 10 , V 20 and MHD were independently and positively associated with the elevated ST-2 change rate. K E Y W O R D S cardiac biomarker, heart dosimetry parameters, radiation-induced heart disease, radiotherapy, sST-2 S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Zeng Z-M, Xu P, Zhou S, et al. Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. J Clin Lab Anal. 2020;34:e23150. https ://doi.

show abstract

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Abstract: Z5 - 22461/2 - 2002-017 (German Federal Office for Radiation Protection).

Cited by 41 publications

References 23 publications

European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer

European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer

Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC

Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST‐2, in thoracic cancer chest radiation

Contact Info

Product

Resources

About